Back to Top
ADVANCING THE FUTURE OF CANCER TREATMENT
At ichorbio, we understand that developing the next breakthrough therapy requires reliable tools and scalable solutions. Our comprehensive range of research biosimilars and in vivo antibodies supports your journey from initial screening through preclinical development, helping you validate targets and accelerate your pipeline with confidence.
FEATURED PRODUCT CATEGORIES
CITED BY TEAMS AT
Loading...
Comprehensive Research Biosimilars
Transform your therapeutic development process with our extensive portfolio of research-grade biosimilars. Whether you're developing new checkpoint inhibitors or exploring novel combination therapies, our validated antibodies provide the reliable benchmarking tools you need. Every product is backed by detailed analytical data, supporting your regulatory documentation requirements and accelerating your path to clinical trials.
Validated In Vivo Solutions
Move your research forward with our selection of in vivo antibodies, specifically developed for preclinical research. Each batch undergoes rigorous testing and is provided with comprehensive documentation, enabling seamless integration into your development pipeline. Our bulk supply capabilities ensure consistent availability throughout your development journey.
Ready to accelerate your development pipeline?
Essential Controls for Validated Research
Success in therapeutic development demands reproducible results. Our isotype controls are manufactured to the same exacting standards as our research antibodies, with low endotoxin levels suitable for in vivo applications. Available in bulk quantities, they provide the experimental validation needed for confidence in your research outcomes.
NEW PRODUCTS
View More
At the coalface of I-O research - biosimilars, bispecifics, ADCs, in vivo antibodies and isotype controls.
Scaling Your Bioprocess Development
For biotechnology companies and contract research organizations, our bulk anti-human antibodies deliver the consistent quality and scale needed for process development. With low endotoxin levels and gram-scale availability, these tools support your manufacturing development while maintaining cost-effectiveness. Our technical team provides expertise for seamless integration into your workflows.
CITATIONS
Latest Publications Featuring ichorbio Products
Loading...
Your Partner in Development
From early-stage research through preclinical development, ichorbio provides the tools and support you need to advance your pipeline. Our commitment to quality, comprehensive documentation, and reliable bulk supply helps accelerate your journey from innovative concept to breakthrough therapy.
-
Posted: December 22, 2025Categories: ichorbio Citations (Resources)
Read more »The Phosphatase Factor: PPP2R2A Insufficiency Sensitizes NSCLC to PD-L1 Blockade via cGAS-STING Activation
The Genomic Stability-Immunity Axis
In the evolving landscape of cancer immunotherapy, the transition from "cold" to "hot" tumor microenvironments (TMEs) remains a primary therapeutic objective. A seminal paper recently published in...
-
Posted: December 20, 2025Categories: ichorbio Citations (Resources)
Read more »Decoding the Mineralized Microenvironment: Autonomous Paracrine Signaling and High-Fidelity Drug Response in a Nanoscale Bone-on-a-Chip
For decades, the primary challenge in bone tissue engineering has been the "growth factor paradox." Standard in-vitro models typically rely on supraphysiological concentrations of recombinant proteins, such as RANKL and M-CSF...
-
Posted: December 16, 2025Categories: ichorbio Citations (Resources)
Read more »Cytokine-Controlled Vulnerability: How TNF-α and IFN-γ Shape the Therapeutic Window for CD70-Targeted Immunotherapy in AML
How lirilumab (ICH4067) and monalizumab (ICH4071) exposed an IFN-γ–driven inhibitory shield that limits NK-cell immunotherapy
The promise of CD70-targeted therapies...
